To compare the frequency of severe hypoglycaemia during insulin lispro and human regular insulin in type 1 diabetic patients.
There were several potential sources of bias in the review: the literature search was limited to the database held by Eli Lilly; all the authors acknowledge a financial relationship with Eli Lilly; one study (reference 15 in the review) was entered in the meta-analysis as two separate trials, and the reasons for this were not stated; seven of the eight included studies had a common author, who was an employee of Eli Lilly; no mention was made of ensuring the exclusion of duplicated patients; no details were given of the methods used to select the primary studies or to extract the data, such as the number of reviewers involved and whether decisions were made independently. Validity was said to have been assessed by reviewing study design and implementation, but no further comment was made concerning the quality of the implementation of trials. More comprehensive details of the participants' characteristics would have been welcome.
The results from the review would be strengthened by clarification of the potential sources of bias highlighted.
Implications of the review for practice and research
Practice: The authors suggest that the use of lispro insulin in reducing the incidence of severe hypoglycaemia can reduce risks during intensive insulin therapy, restore the counter regulatory response to hypoglycaemia, improve hypoglycaemic awareness among type 1 diabetics, and reduce both somatic morbidity and psychological anxiety associated with hypoglycaemia.
Research: The authors did not state any implications for further research.
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